Goresp Digihaler (Budesonide, Formoterol Fumarate Dihydrate)

Goresp Digihaler is indicated for the long‑term, regular maintenance treatment of two chronic respiratory conditions.

• Asthma maintenance therapy in patients requiring both anti‑inflammatory and bronchodilator effects.
• COPD maintenance therapy to reduce exacerbations and improve lung function.
• Patients who need a once‑daily inhaled corticosteroid/long‑acting β2‑agonist combination.
• Use as part of a comprehensive asthma or COPD management plan that includes trigger avoidance and regular monitoring.

The safety profile of Goresp Digihaler reflects the known effects of inhaled corticosteroids and long‑acting β2‑agonists.

Common

• Hoarseness or throat irritation.
• Cough after inhalation.
• Oral candidiasis (thrush).
• Headache.
• Nasal congestion.

Serious

• Paradoxical bronchospasm.
• Severe allergic reaction (anaphylaxis).
• Decreased bone mineral density with long‑term use.
• Glaucoma or cataract progression.

Before prescribing Goresp Digihaler, clinicians should consider several precautionary factors to ensure safe use.

• Assess for active or untreated infections, especially tuberculosis, before initiating therapy.
• Monitor patients for signs of oral thrush and advise rinsing mouth after each dose.
• Use with caution in patients with a history of cardiovascular disease, arrhythmias, or hypertension.
• Evaluate bone health in long‑term users, particularly postmenopausal women.
• Consider potential effects on glucose control in diabetic patients.
• Avoid abrupt discontinuation; taper if therapy is stopped.

Goresp Digihaler may interact with other medicines that affect the respiratory or cardiovascular systems.

Avoid

• Concomitant use of non‑selective β‑blockers, which can reduce bronchodilator effectiveness.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) that may increase systemic exposure to budesonide.

Use with caution

• Other inhaled or oral corticosteroids, which can increase risk of systemic steroid effects.
• Monoamine oxidase inhibitors or tricyclic antidepressants, which may potentiate β2‑agonist cardiac effects.
• Diuretics or antihypertensives, as formoterol can cause transient tachycardia.
• Anticholinergic bronchodilators, requiring monitoring for additive airway effects.